Drugs / CD19 and CD22 targeted CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05651100 | Dec 2022 → Dec 2024 | B-cell non-Hodgkin lymphoma | Kecellitics Biotech Company Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 and CD22 targeted CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05651100 ↗ |
| Modality | Cell therapy | “CD19 and CD22 targeted CAR-T cells” NCT05651100 ↗ |
| Target | CD19 | “CD19 and CD22 targeted CAR-T cells” NCT05651100 ↗ |
| Target | CD22 | “CD19 and CD22 targeted CAR-T cells” NCT05651100 ↗ |